Fundraising FoxTurn Therapeutics
Westlake Village, US
Find your way into Turn Therapeutics
Sign up to see every warm intro you have to Turn Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Turn Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Turn Therapeutics develops topical therapies for skin diseases using its proprietary PermaFusion drug delivery platform. The company's lead program, GX-03, is designed to treat moderate to severe eczema by reducing IL-36 signaling and downstream inflammatory cytokines.
Founders & leadership
BB
NS
Neilesh Shailesh GhodadraExecutive
Board
MW
Martin William DewhurstBoard director
AG
Andrew GengosBoard director
AF
Arthur F GoldenBoard director
KK
Kent KesterBoard director
Reported raises · per SEC filings
Form D private placements$1.6M disclosed across 1 round · 2026
▶$1.6MraisedAug 2026 · 8 investors · BiotechnologyRule 506(b)
▶$1.6MraisedAug 2026 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bradley BurnamExecutive Officer, Director
- Zuraiz ChaudharyExecutive Officer
- Martin William DewhurstDirector
- Andrew GengosDirector
- Arthur F GoldenDirector
- Kent KesterDirector
- Neilesh Shailesh GhodadraExecutive Officer, Director
- Amount sold
- $1.6M
- Minimum investment
- $15K
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Turn Therapeutics do?
- Turn Therapeutics develops topical therapies for skin diseases using its proprietary PermaFusion drug delivery platform. The company's lead program, GX-03, is designed to treat moderate to severe eczema by reducing IL-36 signaling and downstream inflammatory cytokines.
- Who founded Turn Therapeutics?
- Turn Therapeutics was founded by Bradley Burnam.
- How much funding has Turn Therapeutics raised?
- Turn Therapeutics has disclosed $1.6M raised across 1 round.
- Where is Turn Therapeutics headquartered?
- Turn Therapeutics is headquartered in Westlake Village, US.